Combined treatment with a new biscarbodithioate C9G2DTC and BGDTC for mobilizing cadmium deposits in rats.

The cadmium mobilizing efficiency of a combined treatment with a novel cadmium chelating agent disodium N,N'-bis(D-glucosyl)-1,9-nonanediamine-N,N'-biscarbodithioate++ + (C9G2DTC) and with sodium N-benzyl-D-glucamine-N-carbodithioate (BGDTC) was evaluated in albino rats. They received 109Cd intraperitoneally once and 1 week later chelation therapy six times over 12 days at 2-day intervals. The treatment groups were: 1, control; 2, BGDTC six times; 3, C9G2DTC six times; 4, C9G2DTC three times followed by BGDTC three times; 5, C9G2DTC twice followed by BGDTC four times; 6, C9G2DTC once followed by BGDTC five times. The radioactivity in liver, kidney and brain was determined 19 days after 109Cd administration. Results were expressed as a percentage of the 109Cd dose and differences were analyzed by Duncan's multiple range test (P < 0.05). Treatment with C9G2DTC resulted in higher Cd reduction in the liver and lower in the kidney than with BGDTC, which is in agreement with our previous findings. Combined treatment resulted in a greater reduction of Cd in the liver and kidney than by using either chelating agent alone, irrespective of the number of C9G2DTC or BGDTC treatments, and without causing redistribution to the brain. The important aspect of this work is that C9G2DTC--the novel cadmium chelating agent which is extremely efficient in reducing Cd liver deposits and about three times more toxic than BGDTC--has to be used only once at the beginning of the treatment to obtain optimal reduction of aged organ cadmium deposits.